Bruce Levine | Barbara and Edward Netter Professor in Cancer Gene Therapy
Perelman School of Medicine University of Pennsylvania

Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, is the Founding Director of the Clinical Cell and Vaccine Production Facility (CVPF) in the Department of Pathology and Laboratory Medicine and the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania. He received a B.A. (Biology) from Penn and a Ph.D. in Immunology and Infectious Diseases from Johns Hopkins. First-in-human adoptive immunotherapy trials include the first use of a lentiviral vector, the first infusions of gene edited cells, and the first use of lentivirally-modified cells to treat cancer. Dr. Levine is co-inventor of the first FDA approved gene therapy (Kymriah), chimeric antigen receptor T cells for leukemia and lymphoma, licensed to Novartis. Dr. Levine is co-inventor on 33 issued US patents and co-author of >200 manuscripts and book chapters with a Google Scholar citation h-index of 114. He is a Co-Founder of Tmunity Therapeutics, and of Capstan Therapeutics both spinouts of the University of Pennsylvania. Dr. Levine is a recipient of the William Osler Patient Oriented Research Award, the Wallace H. Coulter Award for Healthcare Innovation, the National Marrow Donor Program/Be The Match ONE Forum Dennis Confer Innovate Award, the American Society for Gene and Cell Therapy Jerry Mendell Award for Translational Science, the International Society for Cell and Gene Therapy Career Achievement Award in Cell and Gene Therapy, the Richard N. Merkin Prize in Biomedical Technology, and is a Past-President of the ISCT. He has written for Scientific American and Wired and is dedicated to training the next generation of scientists, public outreach, and expanding global and equitable access to advanced therapies.